{
    "2021-11-06": [
        [
            {
                "time": "",
                "original_text": "葛兰勇进，高瓴撤退，CXO 困境下的“旗手”与“叛徒”",
                "features": {
                    "keywords": [
                        "葛兰",
                        "高瓴",
                        "CXO",
                        "困境",
                        "旗手",
                        "叛徒"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "CXO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "CRO行业三季报总结：公募高配，估值高企",
                "features": {
                    "keywords": [
                        "CRO",
                        "三季报",
                        "公募",
                        "估值",
                        "高配",
                        "高企"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "预见2022：《2021年中国医药研发外包(CRO)行业全景图谱》(附市场现状、竞争格局和发展趋势等)",
                "features": {
                    "keywords": [
                        "2022",
                        "2021",
                        "医药",
                        "CRO",
                        "行业",
                        "全景图谱",
                        "市场现状",
                        "竞争格局",
                        "发展趋势"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "盘点 | 上海医药、罗欣药业、烨辉医药、翰森制药等多家公司引进新药，它们有何亮点？",
                "features": {
                    "keywords": [
                        "上海医药",
                        "罗欣药业",
                        "烨辉医药",
                        "翰森制药",
                        "新药",
                        "亮点"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}